Sep 14, 2026 04:29AM
Sep 14, 2026 04:29AM
Sep 13, 2026 09:55PM
Sep 13, 2026 09:47PM
Sep 13, 2026 09:45PM
Sep 13, 2026 09:45PM
Sep 8, 2026 09:01AM Imfinzi plus tarlatamab shows survival gains in lung cancer trial
Sep 8, 2026 09:00AM
Sep 8, 2026 07:50AM
Sep 8, 2026 07:50AM
Sep 7, 2026 05:55PM
Sep 4, 2026 07:03PM
Sep 4, 2026 03:41PM
Sep 1, 2026 07:00AM AstraZeneca closes $600M deal for lung cancer drug Zegfrovy
Sep 1, 2026 07:00AM
Sep 1, 2026 06:09AM
Aug 27, 2026 07:00AM
Aug 26, 2026 09:20AM
Aug 26, 2026 07:00AM
Aug 26, 2026 07:00AM
Aug 17, 2026 07:30AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
Aug 17, 2026 07:00AM
Aug 17, 2026 02:30AM
Aug 17, 2026 02:30AM
Jul 27, 2026 06:06AM
Jun 22, 2026 08:30AM
Jun 15, 2026 03:00AM
Jun 12, 2026 06:44PM TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
Jun 12, 2026 02:03PM
Jun 2, 2026 08:02AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM
May 28, 2026 09:18PM
May 28, 2026 12:42PM
May 27, 2026 04:04AM FDA extends review period for AstraZeneca breast cancer drug camizestrant
May 22, 2026 10:17AM
May 22, 2026 10:16AM
May 22, 2026 09:30AM
May 22, 2026 09:30AM
May 22, 2026 08:00AM
May 22, 2026 08:00AM
May 22, 2026 07:00AM AstraZeneca to present Phase III cancer data at ASCO 2026
May 22, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 05:07AM
May 15, 2026 09:52PM
May 15, 2026 06:31PM
May 14, 2026 07:00AM Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder
May 1, 2026 05:44AM

330,906 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All